advanced search

Adare Pharma Solutions

Adare Pharmaceuticals is a technology-driven CDMO providing product development through to commercial manufacturing expertise focused on oral dosage forms. Adare’s proprietary technology portfolio encompasses ODT’s, taste masking and customised drug release.


Visit Website

Headquarters
Adare Pharma Solutions
Princeton Pike Corporate Center
1200 Lenox Drive, Suite 100
Lawrenceville
NJ 08648
United States

Phone / Contact

T: +1 877 731 5116

Connect

Adare Pharma Solutions is a global technology-driven specialty CDMO providing turnkey product development through to commercial manufacturing expertise focused on oral dosage forms for the pharmaceutical market. Adare’s proprietary technology platforms specialise in ODTs, taste masking and customised drug release.

Adare Pharma Solutions rebranded from Adare Pharmaceuticals in September 2020 when it was acquired by private equity firms Thomas H Lee Partners and Frazier Healthcare Partners. Earlier in 2020, Adare acquired Orbis Biosciences, broadening its oral delivery technology portfolio and also moving into the field of injectables for the first time.

Adare was formed in 2015 when TPG Capital acquired and renamed Aptalis, but the company has 30 years of proven legacy with roots in companies such as Eurand and Aptalis. Adare has multiple facilities in the US and Europe, and has developed and manufactured more than 40 products sold by partners in more than 100 countries globally.

0

SHARE

Articles by Adare Pharma Solutions

INTERVIEW
Maria Flynn
INTERVIEW WITH MARIA FLYNN, ADARE PHARMACEUTICALS
Adare Pharma's Maria Flynn talks with ONdrugDelivery about trends in the oral drug development and delivery space, completing the Orbis Biosciences acquisition during a global pandemic, and how the excellent technology portfolio and strategic fit between Orbis and Adare form part of the combined organisation’s unique story.
GI/ORAL
Dr Nathan Dormer
SINGLE-STEP FUNCTIONAL COATINGS FOR INCREASED EFFICIENCIES
In this article about oral drug innovation, Cory Berkland and Nathan Dormer focus on how enterics and reverse enterics are applied into dosage forms, and discuss the future of this class of drug formulation technology.
GI/ORAL
Dr Cory Berkland
THE EMERGENCE OF CONTROLLED-RELEASE POWDERS FOR ORAL ADMINISTRATION
Cory Berkland and Nathan Dormer look at what controlled-release powder delivery systems can offer, noting that a rising number of pharmaceutical companies and manufacturing organisations are incorporating controlled-release powder manufacturing to their portfolios.
Top